POXEL: 2015 Financial Calendar

LYON, France--(BUSINESS WIRE)-- Regulatory News:

POXEL (Paris:POXEL) (Euronext - FR0012432516), an independent French biopharmaceutical company focused on the development of antidiabetic drugs, today announces its schedule for the publication of financial information for 2015.

Évent     Date *
2014 Full-Year Sales     March 16, 2015
2014 Full-Year Financial statements     April 30, 2015
2015 Q1 Sales     May 5, 2015
Annual Shareholders’ Meeting     June 16, 2015
2015 Q2 Sales     July 15, 2015
2015 June 30th, Financial statements     August 31, 2015
2015 Q3 Sales     October 22, 2015
2015 Full-Year Sales     January 28, 2016

* Subject to modification. Press releases are published after market closes.

About Poxel

Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has entered clinical development in Japan. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)

Investor / Media Relations - France
Florent Alba/Nicolas Merigeau
+33 1 44 71 98 55
Investor / Media Relations – EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer or Anca Alexandru
+49 89 2424 3494

Source: POXEL